Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, Koo HH, Cho EJ, Lee SK, Lim DH.

J Hematol Oncol. 2017 May 16;10(1):108. doi: 10.1186/s13045-017-0477-0.

2.

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.

Casey DL, Kushner BH, Cheung NK, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):393-400. doi: 10.1016/j.ijrobp.2016.05.020. Epub 2016 May 27.

PMID:
27473818
3.

High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas.

Choi YB, Yi ES, Lee JW, Yoo KH, Sung KW, Koo HH.

J Korean Med Sci. 2016 Jul;31(7):1055-62. doi: 10.3346/jkms.2016.31.7.1055. Epub 2016 May 16.

4.

Primary intrathoracic malignant neurogenic tumor: report of three cases and comparison with benign neurogenic tumors resected at our institution.

Kawaguchi T, Kawai N, Watanabe T, Yasukawa M, Morita K, Ohbayashi C, Tojo T.

Surg Case Rep. 2015 Dec;1(1):6. doi: 10.1186/s40792-014-0013-1. Epub 2015 Jan 28.

5.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

6.

Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma.

Harreld JH, Bratton EM, Federico SM, Li X, Grover W, Li Y, Kerr NC, Wilson MW, Hoehn ME.

Pediatr Blood Cancer. 2016 Apr;63(4):627-33. doi: 10.1002/pbc.25847. Epub 2015 Nov 24.

7.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

8.

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes.

Khan FH, Pandian V, Ramraj S, Natarajan M, Aravindan S, Herman TS, Aravindan N.

BMC Cancer. 2015 Jul 10;15:514. doi: 10.1186/s12885-015-1463-y.

9.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK.

Oncoimmunology. 2015 May 22;4(7):e1016704. eCollection 2015 Jul.

10.

The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma.

Federico SM, Brady SL, Pappo A, Wu J, Mao S, McPherson VJ, Young A, Furman WL, Kaufman R, Kaste S.

Pediatr Blood Cancer. 2015 Jun;62(6):976-81. doi: 10.1002/pbc.25400. Epub 2015 Jan 13.

11.

Mechanisms of neuroblastoma regression.

Brodeur GM, Bagatell R.

Nat Rev Clin Oncol. 2014 Dec;11(12):704-13. doi: 10.1038/nrclinonc.2014.168. Epub 2014 Oct 21. Review.

12.

Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.

Muthu M, Cheriyan VT, Munie S, Levi E, Frank J, Ashour AE, Singh M, Rishi AK.

PLoS One. 2014 Jul 17;9(7):e102567. doi: 10.1371/journal.pone.0102567. eCollection 2014.

13.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

14.

Methods for image guided and intensity modulated radiation therapy in high-risk abdominal neuroblastoma.

Pai Panandiker AS, Beltran C, Gray J, Hua C.

Pract Radiat Oncol. 2013 Apr-Jun;3(2):107-14. doi: 10.1016/j.prro.2012.04.002. Epub 2012 May 3.

15.

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Federico SM, Allewelt HB, Spunt SL, Hudson MM, Wu J, Billups CA, Jenkins J, Santana VM, Furman WL, McGregor LM.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e6-e12. doi: 10.1097/MPH.0000000000000148.

16.

Optimal time to start peripheral blood stem cell collection in children with high-risk solid tumors.

Sung KW, Chueh HW, Lee NH, Kim DH, Lee SH, Yoo KH, Koo HH, Kang ES, Kim DW.

J Korean Med Sci. 2014 Jan;29(1):110-6. doi: 10.3346/jkms.2014.29.1.110. Epub 2013 Dec 26.

17.
18.

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.

Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA.

Bone Marrow Transplant. 2013 Aug;48(8):1056-64. doi: 10.1038/bmt.2012.284. Epub 2013 Feb 18.

19.

Hematologic recovery after tandem high-dose chemotherapy and autologous stem cell transplantation in children with high-risk solid tumors.

Son MH, Kim DH, Lee SH, Yoo KH, Sung KW, Koo HH, Kim JY, Cho EJ, Kang ES, Kim DW.

J Korean Med Sci. 2013 Feb;28(2):220-6. doi: 10.3346/jkms.2013.28.2.220. Epub 2013 Jan 29.

20.

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.

Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA.

Bone Marrow Transplant. 2013 Jul;48(7):947-52. doi: 10.1038/bmt.2012.276. Epub 2013 Jan 21.

Supplemental Content

Support Center